ImmunoGen, Inc. ( IMGN Quick Quote IMGN - Free Report) reported earnings of 16 cents per share for the fourth quarter of 2020 compared with the year-ago earnings of 3 cents. The Zacks Consensus Estimate stood at a loss of 4 cents per share.
Revenues came in at $85.8 million, which also beat the Zacks Consensus Estimate of $51 million. Revenues were up 91.1% year over year, mainly driven by higher license and milestone fees.
ImmunoGen’s shares soared 30.3% on Feb 12, following the strong quarterly results and bullish outlook for 2021. Shares of the company have gained 54.9% so far this year compared with the
industry’s increase of 8.3%. Quarter in Details
For the fourth quarter, Immunogen reported license and milestone fees of $62.4 million compared with $29.6 million in the year-ago period. The significant rise was due to recognition of $60.5 million from
Jazz Pharmaceuticals ( JAZZ Quick Quote JAZZ - Free Report) as upfront payment related to a collaboration agreement for hematology programs.
Fourth-quarter revenues included $23.4 million in non-cash royalty revenues, up 52.6% year over year, riding on rising global sales of its partner
Roche’s ( RHHBY Quick Quote RHHBY - Free Report) Kadcyla.
During the quarter, research and development expenses increased 51.9% from the year-ago level to $39.6 million. The significant increase was due to higher clinical activity related to its lead pipeline candidate, mirvetuximab soravtansine, and to support its potential commercial launch expected next year.
General and administrative expenses decreased 0.7% to $9.7 million in the fourth quarter of 2020.
ImmunoGen’s cash and cash equivalents increased to $293.9 million at the end of December 2020 compared with $188.2 million at the end of September 2020.
Immunogen reported revenues of $132.3 million, up 60.8% year over year. The company recorded a loss of 25 cents per share for 2020, 64.3% narrower than the year-ago period.
ImmunoGen is evaluating its lead pipeline candidate, mirvetuximab soravtansine, in a pivotal study — SORAYA — in platinum-resistant ovarian cancer patients. The company expects the data from this study to form the basis of the candidate’s regulatory filing under accelerated pathway for ovarian cancer. Top-line data from the SORAYA study is expected in the third quarter of 2021. A biologics license application is expected to be filed by 2021-end.
The company is enrolling patients in the confirmatory phase III MIRASOL study, which compared, mirvetuximab soravtansine, head-to-head with single agent chemotherapy in platinum-resistant ovarian cancer patients with high folate receptor alpha expression. Top-line data is expected in the first half of 2022. Data from the MIRASOL study will support its continued approval of the candidate in the indication.
In October, the company entered into an exclusive collaboration agreement with China-based Huadong Medicine to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan. The National Medical Products Administration of China has accepted an investigational new drug (“IND”) application to support initiation of clinical study in the country.
The company has another promising candidate, IMGN632, in its pipeline. It is being developed in clinical studies as monotherapy or in combination with
Bristol-Myers’ ( BMY Quick Quote BMY - Free Report) Vidaza or AbbVie/Roche’s Venclexta for treating acute myeloid leukemia (“AML”). It is also developing IMGN632 monotherapy in a phase I/II in patients with blastic plasmacytoid dendritic cell neoplasm and acute lymphocytic leukemia. During the quarter, the company amended the study to include a pivotal cohort, following a discussion with the FDA.
The company initiated a phase I study on IMGC936 to evaluate it in solid tumors recently. The company will co-develop the candidate with MacroGenics. Initial data from the study is expected later this year or early 2022. The company plans to file an IND application with the FDA for a new candidate, IMGN151, by year-end.
Issues 2021 Guidance
ImmunoGen provided its guidance for revenues, operating expenses and cash resources in 2021. The company expects revenues for the full year to be between $65 million and $75 million. The Zacks Consensus Estimates for 2021 revenues stands at $55.76 million.
The company expects operating expense to be in the range of $200-$210 million. It expects cash and cash equivalents to be between $140 million and $150 million at 2021-end.
It expects cash resources to be enough to fund its operations through the second half of 2022.
Currently, Immunogen is a Zacks Rank #3 (Hold) stock. You can see
. the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>